Celgene vet Daniel takes a startup role at Vividion, with $50M in hand for platform construction
You can count Tom Daniel as the latest big biopharma exec to make the transition to biotech.
The Celgene veteran has taken on the executive …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
